Industry news that matters to you.  Learn more

Technion Researchers Identify a Cluster of Five Genes in the Blood that Predict Parkinson’s Disease

Technion researchers from the Rappaport Faculty of Medicine have identified five genes that predict Parkinson’s disease, reports the scientific journal Molecular Neurodegeneration. The research was conducted by Dr. Silvia Mandel, Vice Director of the Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Teaching, together with her colleagues Prof. Moussa Youdim (Technion), Prof. Judith Aharon (Rambam Medical Center), and Prof. Martin Rabey (Assaf HaRofeh Medical Center), as well as her colleagues from the Universities of Würzburg and Pisa.

Statin Use Appears Associated with Modest Reduction in Parkinson Disease Risk

Regular use of cholesterol-lowering statin drugs may be associated with a modest reduction in risk for developing Parkinson disease, particularly among younger patients, according to a study in the March issue of Archives of Neurology, one of the JAMA/Archives journals.

Biomarker for Huntington’s Disease Identified

Huntington’s disease, a devastating genetic disorder that causes degeneration of nerve cells in the brain, affects more than 15,000 Americans, and at least 150,000 are at risk of developing the disease. There is no known cure or treatment for the disease — which starts with changes in mood, judgment, memory, and other cognitive functions and inevitably leads to increasing physical disability, dementia and death. In a new research paper published in the Proceedings of the National Academy of Sciences Early Edition online, researchers identify a transcriptional biomarker that may assist in the monitoring of disease activity and in the evaluation of new medications.

Study Examines Blood Biomarkers Upon Erythropoietin Treatment of Ischemic Stroke

Researchers at the Max Planck Institute of Experimental Medicine in Goettingen, Germany, led by Prof. Hannelore Ehrenreich, the University of Bremen and University of Hannover, in collaboration with Dr. Andreas Jeromin at Banyan Biomarkers, Inc, in Alachua, FL, have identified a panel of protein-based blood biomarkers in patients treated with erythropoietin (EPO), which correlate with positive outcome in this study.